Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Ionescu

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
The Journal of Clinical Psychiatry|October 9, 2014
Effect of baseline anxious depression on initial and sustained antidepressant response to ketamineDawn F Ionescu, David A Luckenbaugh, Mark J Niciu, et al.
Journal of Affective Disorders|November 4, 2017
Corrigendum to "Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants" [J. Affect. Disord. 208 (2017, Jan. 15) 6-14, doi: 10.1016/j.jad.2016.08.029, Epub 2016 Oct. 1]D Mischoulon, L Hylek, A S Yeung, et al.
The Journal of Clinical Psychiatry|June 13, 2014
Clinical predictors of ketamine response in treatment-resistant major depressionMark J Niciu, David A Luckenbaugh, Dawn F Ionescu, et al.
Depression and Anxiety|July 22, 2021
The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorderElla J Daly, Ibrahim Turkoz, Giacomo Salvadore, et al.
Biological Psychiatry Global Open Science|May 25, 2026
Efficacy and Safety of the Selective, Brain-Penetrant P2X7 Receptor Antagonist JNJ-55308942 (Zanvipixant) in Bipolar Depression: A Phase 2a StudyJames A Palmer, Matthew Klein, Dai Wang, et al.
Biological Psychiatry|December 19, 2012
Acute stress symptoms do not worsen in posttraumatic stress disorder and abuse with a single subanesthetic dose of ketamineMary C Zeng, Mark J Niciu, David A Luckenbaugh, et al.
Pharmacopsychiatry|June 24, 2014
Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamineN B Lundin, M J Niciu, D A Luckenbaugh, et al.
The International Journal of Neuropsychopharmacology|December 25, 2014
Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorderMark J Niciu, David A Luckenbaugh, Dawn F Ionescu, et al.
Journal of Psychiatric Research|August 21, 2014
Riluzole likely lacks antidepressant efficacy in ketamine non-respondersMark J Niciu, David A Luckenbaugh, Dawn F Ionescu, et al.
Molecular Psychiatry|March 12, 2014
Preliminary evidence that early reduction in p11 levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopramP Svenningsson, L Berg, D Matthews, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
The Journal of Clinical Psychiatry|October 9, 2014
Effect of baseline anxious depression on initial and sustained antidepressant response to ketamineDawn F Ionescu, David A Luckenbaugh, Mark J Niciu, et al.
Journal of Affective Disorders|November 4, 2017
Corrigendum to "Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants" [J. Affect. Disord. 208 (2017, Jan. 15) 6-14, doi: 10.1016/j.jad.2016.08.029, Epub 2016 Oct. 1]D Mischoulon, L Hylek, A S Yeung, et al.
The Journal of Clinical Psychiatry|June 13, 2014
Clinical predictors of ketamine response in treatment-resistant major depressionMark J Niciu, David A Luckenbaugh, Dawn F Ionescu, et al.
Depression and Anxiety|July 22, 2021
The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorderElla J Daly, Ibrahim Turkoz, Giacomo Salvadore, et al.
Biological Psychiatry Global Open Science|May 25, 2026
Efficacy and Safety of the Selective, Brain-Penetrant P2X7 Receptor Antagonist JNJ-55308942 (Zanvipixant) in Bipolar Depression: A Phase 2a StudyJames A Palmer, Matthew Klein, Dai Wang, et al.
Biological Psychiatry|December 19, 2012
Acute stress symptoms do not worsen in posttraumatic stress disorder and abuse with a single subanesthetic dose of ketamineMary C Zeng, Mark J Niciu, David A Luckenbaugh, et al.
Pharmacopsychiatry|June 24, 2014
Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamineN B Lundin, M J Niciu, D A Luckenbaugh, et al.
The International Journal of Neuropsychopharmacology|December 25, 2014
Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorderMark J Niciu, David A Luckenbaugh, Dawn F Ionescu, et al.
Journal of Psychiatric Research|August 21, 2014
Riluzole likely lacks antidepressant efficacy in ketamine non-respondersMark J Niciu, David A Luckenbaugh, Dawn F Ionescu, et al.
Molecular Psychiatry|March 12, 2014
Preliminary evidence that early reduction in p11 levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopramP Svenningsson, L Berg, D Matthews, et al.
Pageof 8